Sarcopenia Drug Combination
Sarcopenia
DiscoveryLead shows potential in models
Key Facts
About Centenara Labs
Centenara Labs is a pioneering longevity-focused biotech that builds and invests in a diversified portfolio of companies targeting geriatric diseases through the lens of aging biology. Its strategy involves de-risking early scientific discoveries by providing a platform of experienced drug developers, business leaders, and capital. With a pipeline built around the hallmarks of aging, the company has progressed two ophthalmology programs into the clinic and is advancing several pre-clinical assets in fibrosis, cancer, and sarcopenia, aiming to create optimal exit scenarios to fund new ventures.
View full company profileTherapeutic Areas
Other Sarcopenia Drugs
| Drug | Company | Phase |
|---|---|---|
| BIO101 (20-hydroxyecdysone) | Biophytis | Phase 3 |
| DT-201 | Dystrogen Therapeutics | Preclinical |